Idioma:

Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy

Italiano, Domenico ; Bianchini, Elisa ; Ilardi, Maura ; Cilia, Roberto ; Pezzoli, Gianni ; Zanettini, Renzo ; Vacca, Laura ; Stocchi, Fabrizio ; Bramanti, Placido ; Ciurleo, Rosella ; Di Lorenzo, Giuseppe ; Polimeni, Giovanni ; de Luise, Cynthia ; Ross, Douglas ; Rijnbeek, Peter ; Sturkenboom, Miriam ; Trifirò, Gianluca

Journal of Neural Transmission, 2015-06, Vol.122 (6), p.799-808 [Periódico revisado por pares]

Vienna: Springer Vienna

Texto completo disponível

Citações Citado por

Enviar para

Título:
Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy
Autor: Italiano, Domenico ; Bianchini, Elisa ; Ilardi, Maura ; Cilia, Roberto ; Pezzoli, Gianni ; Zanettini, Renzo ; Vacca, Laura ; Stocchi, Fabrizio ; Bramanti, Placido ; Ciurleo, Rosella ; Di Lorenzo, Giuseppe ; Polimeni, Giovanni ; de Luise, Cynthia ; Ross, Douglas ; Rijnbeek, Peter ; Sturkenboom, Miriam ; Trifirò, Gianluca
Assuntos: Aged ; Antiparkinson Agents - adverse effects ; Antiparkinson Agents - therapeutic use ; Cohort Studies ; Echocardiography ; Ergolines - adverse effects ; Ergolines - therapeutic use ; Female ; Guideline Adherence ; Heart Valve Diseases - epidemiology ; Heart Valve Diseases - physiopathology ; Heart Valve Diseases - prevention & control ; Heart Valves - drug effects ; Heart Valves - physiopathology ; Humans ; Incidence ; Italy ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neurology ; Neurology and Preclinical Neurological Studies - Original Article ; Neurosciences ; Parkinson Disease - drug therapy ; Parkinson Disease - epidemiology ; Parkinson Disease - physiopathology ; Pergolide - adverse effects ; Pergolide - therapeutic use ; Practice Guidelines as Topic ; Prevalence ; Psychiatry ; Retrospective Studies ; Risk Factors ; Supranuclear Palsy, Progressive - drug therapy ; Supranuclear Palsy, Progressive - epidemiology ; Supranuclear Palsy, Progressive - physiopathology
É parte de: Journal of Neural Transmission, 2015-06, Vol.122 (6), p.799-808
Descrição: On June 2008, the European Medicines Agency (EMA) introduced changes to the Summary of Product Characteristics (SPC) for cabergoline and pergolide, to reduce the risk of cardiac valvulopathy in users of these drugs. To assess the effectiveness of EMA recommendations in Italian clinical practice, we retrospectively reviewed medical charts of patients with degenerative Parkinsonism treated with cabergoline in three large Italian clinics between January 2006 and June 2012. The prevalence and the severity of cardiac valve regurgitation were assessed in patients who stopped cabergoline therapy prior to June 2008 or continued therapy after that date. In addition, the proportion of patients undergoing echocardiographic examination in each cohort was evaluated. A total of 61 patients were available for evaluation. The proportion of patients who underwent a baseline echocardiographic examination increased from 64 % in the period before the 2008 SPC changes to 71 % among those who continued treatment after that date. However, only 18 and 29 % of patients underwent at least two echocardiographic examinations during the pre-SPC and cross-SPC change period, respectively. No severe cardiac valve regurgitation was documented in any of the study patients using cabergoline either prior or after 26th June 2008. Our findings show that the 2008 changes to the SPC resulted in an increase in physicians’ awareness of cabergoline-induced valvulopathy risk in Italy. However, only a small percentage of patients underwent serial echocardiography. Further efforts are needed to achieve better compliance with the prescribing guidelines for cabergoline treated patients in clinical practice.
Editor: Vienna: Springer Vienna
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy

Vienna: Springer Vienna

Buscando em bases de dados remotas. Favor aguardar.